Successful First Implantation of ProStyle M® Mitral Valve by KingstronBio Marks a New Era in Cardiac Care

First Successful Implantation of ProStyle M® Mitral Valve System

On March 12, 2026, a groundbreaking achievement was realized in the world of cardiac care with the first successful implantation of the ProStyle M® Transcatheter Mitral Valve System by KingstronBio. Conducted in Shanghai, this significant medical procedure was part of a national multicenter confirmatory study and underscores the potential of this innovative technology in treating mitral valve regurgitation, a prevalent heart condition globally.

Background of the ProStyle M® System

Developed by KingstronBio Technology (Changshu) Co., Ltd., the ProStyle M® valve is designed with a focus on safety and effectiveness. The implantation procedure was executed by renowned cardiac surgeons, Professors Wang Chunsheng and Wei Lai, from the Zhongshan Hospital affiliated with Fudan University. This event marks not only the commencement of a pivotal clinical trial but also highlights KingstronBio's commitment to advancing cardiac treatment.

Prior to its commercial debut, the ProStyle M® system underwent a comprehensive two-year First-in-Man (FIM) study that included 10 patients, with an average age of 71. The outcomes from this study were promising, indicating an excellent anchoring performance, as there was no regurgitation noted among the participants. Such results provide a strong foundation for the larger multicenter study that KingstronBio is now embarking upon.

Challenges in Mitral Valve Replacement

Mitral regurgitation is considered the most common valvular heart disease in China. The implementation of transcatheter mitral valve replacement (TMVR) procedures often faces several technical challenges. These challenges include complex anatomical structures, the risk of left ventricular outflow obstruction, and difficulties associated with the anchoring and sealing capabilities of artificial valves. The ProStyle M® system aims to address these issues effectively.

Innovative Solutions for Cardiac Treatment

One of the innovative features of the ProStyle M® system is its eccentric structural design. This design reduces surgical complexities and minimizes the risk of obstruction in the left ventricular outflow tract, while ensuring a stable anchoring performance and favorable hemodynamics. This represents a significant leap forward in intervention strategies for structural heart diseases.

Moreover, KingstronBio has integrated patented technologies such as Micro-Ex™ and AirBo™ into its valve systems. Micro-Ex™ is a sophisticated anti-calcification treatment process. It effectively removes residual cellular debris, phospholipids, and active groups of glutaraldehyde from the pericardium, significantly delaying calcification of the valve leaflets, and thereby enhancing long-term durability.

AirBo™, on the other hand, concerns the dry storage of bovine pericardial tissue using a special ionic liquid, retaining molecular water to maintain collagen flexibility. Together, these technologies synergize to provide enhanced anti-calcification performance and long-lasting durability of the valve systems in clinical applications.

KingstronBio's Vision and Future

KingstronBio's mission is clear: to innovate within the realm of structural heart diseases while delivering high-quality medical devices to cardiologists in China. The company's research team, comprised of esteemed experts, holds numerous domestic and international patents in biomaterials treatment and valve technology, reflecting a robust commitment to ongoing innovation in cardiac care.

As the clinical study of the ProStyle M® system unfolds, it is anticipated that further evidence will affirm the safety and efficacy of KingstronBio's products, potentially transforming the landscape of treatment options available for individuals suffering from moderate to severe mitral regurgitation.

In conclusion, the successful implantation of the ProStyle M® valve marks not just a milestone for KingstronBio but signifies a broader revolution in cardiac care that promises to provide safer and more effective therapeutic options for patients.